Structure Therapeutics (NASDAQ:GPCR) Reaches New 12-Month Low - What's Next?

Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) shares reached a new 52-week low during trading on Wednesday . The stock traded as low as $13.22 and last traded at $13.91, with a volume of 123479 shares. The stock had previously closed at $14.15.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on GPCR. HC Wainwright reaffirmed a "buy" rating and set a $80.00 target price on shares of Structure Therapeutics in a research report on Thursday, December 19th. Stifel Nicolaus started coverage on Structure Therapeutics in a report on Wednesday, January 8th. They issued a "buy" rating and a $50.00 price objective for the company. William Blair began coverage on shares of Structure Therapeutics in a report on Friday, February 28th. They set an "outperform" rating on the stock. Finally, JMP Securities restated a "market outperform" rating and issued a $91.00 price target on shares of Structure Therapeutics in a report on Wednesday, December 18th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $81.29.

Structure Therapeutics Trading Up 10.0 %

The stock has a 50-day moving average price of $20.98 and a two-hundred day moving average price of $29.11. The stock has a market cap of $1.00 billion, a price-to-earnings ratio of -23.63 and a beta of -1.35.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.01. Research analysts predict that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

Remove Ads

Hedge Funds Weigh In On Structure Therapeutics

Hedge funds have recently made changes to their positions in the company. Deep Track Capital LP raised its stake in shares of Structure Therapeutics by 129.4% in the fourth quarter. Deep Track Capital LP now owns 2,800,000 shares of the company's stock worth $75,936,000 after purchasing an additional 1,579,492 shares during the last quarter. Vestal Point Capital LP increased its holdings in Structure Therapeutics by 50.0% in the 4th quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company's stock worth $46,782,000 after buying an additional 575,000 shares during the period. Boxer Capital Management LLC purchased a new position in Structure Therapeutics during the 4th quarter worth approximately $13,560,000. Marshall Wace LLP lifted its stake in Structure Therapeutics by 339.6% during the 4th quarter. Marshall Wace LLP now owns 583,207 shares of the company's stock valued at $15,817,000 after acquiring an additional 450,531 shares during the period. Finally, Foresite Capital Management VI LLC purchased a new stake in shares of Structure Therapeutics in the 4th quarter valued at $11,390,000. 91.78% of the stock is owned by institutional investors and hedge funds.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.